Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 3:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 74 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Carvedilol Controlled Release (CR), lisinopril
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
ACE-Inhibitors and Angiotensin Receptor Blockers
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia • Decatur, Georgia
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Perindopril, Placebo, Candesartan
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Terminated Phase 2 Interventional Results available

Rhubarb and Angiotensin Converting Enzyme Inhibitor

NCT00672451
Conditions
Diabetic Kidney Disease
Interventions
rhubarb extract, placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
43
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 31 more
Conditions
Fabry Disease, Proteinuria
Interventions
enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 85 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more
Recruiting Phase 2 Interventional

Cardioprotection in AML

NCT04977180
Conditions
AML, Acute Myeloid Leukemia
Interventions
Cardioprotection
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease

NCT00874432
Conditions
Cardiovascular Disease, Chronic Kidney Disease
Interventions
angiotensin converting enzyme inhibitor, lisinopril
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
60 Years to 89 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Hypertension
Interventions
Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
65 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
29
States / cities
Birmingham, Alabama • Mesa, Arizona • Long Beach, California + 26 more
Conditions
Hypertension, Aging, Sedentary Lifestyle
Interventions
Aerobic exercise, Perindopril, Losartan, HCTZ
Behavioral · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
60 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Birmingham, Alabama • Orlando, Florida
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study

NCT01691781
Conditions
Hyperparathyroidism
Interventions
Lisinopril
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Chronic Kidney Disease, Proteinuria
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 16 more
Terminated Phase 3 Interventional Results available

VA NEPHRON-D: Diabetes iN Nephropathy Study

NCT00555217
Conditions
Kidney Disease, Nephropathy, Type 2 Diabetes
Interventions
losartan, lisinopril
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
30
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
Conditions
Angioedema
Interventions
ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio
Conditions
Hypertension, Resistant to Conventional Therapy
Interventions
Equivalent dose enalapril, Equivalent dose lisinopril
Drug
Lead sponsor
Memorial Health University Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Savannah, Georgia
Conditions
de Novo Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Empagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
53
States / cities
Birmingham, Alabama • Sheffield, Alabama • Hawaiian Gardens, California + 40 more
Conditions
Hypertension, Blood Pressure, High
Interventions
Ramipril and hydrochlorothiazide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 51 more
Conditions
Diabetes Mellitus, Diabetic Nephropathy
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
Conditions
Cardiovascular Diseases
Interventions
Telmisartan, Combination of Telmisartan and Ramipril, Ramipril
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
55 Years and older
Enrollment
31,546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
100
States / cities
Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more
Conditions
Chronic Kidney Disease, Proteinuria, Children
Interventions
Finerenone (Kerendia, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 15 more